NYSE$BDX
Becton Dickinson & Co. · Q3 2023 earnings
Q3 2023 earnings · · Investor relations
Briefing
Reported strong performance and progress toward achieving BD 2025 strategy, while advancing innovation pipeline and receiving clearance for updated BD Alaris™ Infusion System.
BD reported a revenue of $4.9 billion, a 5.1% increase as reported and 6.3% on a currency-neutral basis. The company raised its full-year base organic revenue growth guidance and maintained its full-year adjusted EPS guidance.
- Revenue of $4.9 billion increased 5.1% as reported and 6.3% on a currency-neutral basis
- Revenue from base business (which excludes COVID-only diagnostic testing) grew 6.7% as reported, 7.9% currency-neutral or 6.3% organic
- GAAP and adjusted diluted EPS from continuing operations of $1.36 and $2.96, respectively
- Company raises full-year base organic revenue growth guidance; maintains full-year adjusted EPS guidance
Headline financials
Revenue & EPS history
BD · Revenue · Quarterly
$4.88B
Revenue by segment
BD · $2.53B total across 2 segments · Q4 2023
- BD Life Sciences$1.33B+3.3%52.5%
- BD Interventional$1.2B+9.7%47.5%
Forward guidance
The company now expects fiscal year 2023 revenues to be approximately $19.3 billion. Adjusted diluted EPS guidance of $12.10 to $12.32 remains unchanged but reflects absorbing a $0.02 negative impact from the divestiture of the Surgical Instrumentation platform and a $0.05 negative impact from the latest foreign currency rates.
Tailwinds
- Revenue guidance now assumes base business currency-neutral revenue growth of 6.8% to 7.1% before the impact of the Surgical Instrumentation platform divestiture.
- Base organic revenue growth is now expected to be 5.5% to 5.8%, compared to 5.25% to 5.75% previously announced, and continues to reflect fourth quarter organic revenue growth of about 6%.
- Adjusting for the impact of the Surgical Instrumentation platform divestiture lowers the updated base revenue growth guidance by 20 basis points to a range of 6.6% to 6.9%.
- Increased base organic revenue growth guidance of 5.5% to 5.8% is not impacted.
- On a currency-neutral basis, adjusted diluted EPS guidance now represents growth of approximately 10% to 11.5%, an increase of 50 basis points from the company's prior expectation.
Headwinds
- Revenue guidance includes $56 million in year-to-date COVID-only diagnostic testing revenues.
- Based on current rates, foreign exchange continues to represent a reduction of approximately 200 basis points, or approximately $370 million, to total company revenue growth.
- Adjusted EPS guidance reflects absorbing a $0.02 negative impact from the divestiture of the Surgical Instrumentation platform
- Adjusted EPS guidance reflects absorbing a $0.05 negative impact from the latest foreign currency rates.
- Adjusted diluted EPS guidance now includes an estimated headwind from foreign currency of approximately 320 basis points based on current rates, compared to 270 basis points previously.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2023
-0.9%
Avg return
Earnings day
-0.9%
Avg return
5 days after
-0.5%
Avg return
30 days after
38%
28 / 73 earnings
Positive
+8.9%
Q3 2025
Best reaction
-18.1%
Q2 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2026 | -0.7% | -1.1% | +4.6% | |
| Q1 2026 | -1.3% | +6.5% | -1.2% | |
| Q4 2025 | +0.6% | +7.2% | +10.0% | |
| Q3 2025 | +8.9% | +13.1% | +11.6% | |
| Q2 2025 | -18.1% | -20.3% | -16.7% | |
| Q1 2025 | -6.3% | -5.3% | -5.3% | |
| Q4 2024 | -3.5% | -3.7% | -8.3% | |
| Q3 2024 | +0.3% | -2.3% | +0.6% | |
| Q2 2024 | +0.4% | +1.5% | -0.7% | |
| Q1 2024 | -0.7% | -0.1% | -1.5% | |
| Q4 2023 | -8.3% | -8.8% | -9.2% | |
| Q3 2023 | -2.0% | +1.8% | +0.8% | |
| Q2 2023 | -3.8% | -5.3% | -4.5% | |
| Q1 2023 | -3.3% | -0.4% | -6.7% | |
| Q4 2022 | +4.3% | +1.9% | +13.4% | |
| Q3 2022 | +3.8% | +4.2% | +3.2% | |
| Q2 2022 | +1.7% | -1.4% | -0.5% | |
| Q1 2022 | +4.7% | +7.7% | +7.3% | |
| Q4 2021 | -1.3% | -1.4% | -1.2% | |
| Q3 2021 | -5.4% | -6.3% | +1.2% | |
| Q2 2021 | -4.2% | -3.4% | -3.6% | |
| Q1 2021 | -2.4% | -2.6% | -5.5% | |
| Q4 2020 | -0.1% | +1.5% | +2.5% | |
| Q3 2020 | -9.5% | -10.0% | -17.4% | |
| Q2 2020 | -1.8% | +1.1% | -6.6% | |
| Q1 2020 | -13.7% | -10.3% | -16.4% | |
| Q4 2019 | -3.8% | -6.1% | -0.7% | |
| Q3 2019 | +3.5% | +7.6% | +9.4% | |
| Q2 2019 | -3.0% | -4.1% | +2.6% | |
| Q1 2019 | -1.7% | -2.0% | -0.2% | |
| Q4 2018 | -0.2% | +2.5% | +1.6% | |
| Q3 2018 | -1.1% | -0.8% | +4.7% | |
| Q2 2018 | -2.4% | -3.8% | -2.3% | |
| Q1 2018 | -1.3% | -3.4% | -0.6% | |
| Q4 2017 | +7.9% | +6.3% | +8.8% | |
| Q3 2017 | -1.9% | -2.1% | -0.9% | |
| Q2 2017 | -1.4% | -0.5% | +3.5% | |
| Q1 2017 | +0.2% | -0.1% | +3.2% | |
| Q4 2016 | +4.9% | +7.1% | -0.8% | |
| Q3 2016 | -1.2% | -0.9% | +0.9% | |
| Q2 2016 | +2.0% | — | — | |
| Q1 2016 | -4.9% | — | — | |
| Q4 2015 | +3.8% | — | — | |
| Q3 2015 | -3.2% | — | — | |
| Q2 2015 | +0.7% | — | — | |
| Q1 2015 | +2.4% | — | — | |
| Q4 2014 | -0.2% | — | — | |
| Q3 2014 | -2.8% | — | — | |
| Q2 2014 | -0.4% | — | — | |
| Q1 2014 | +1.8% | — | — | |
| Q4 2013 | +0.5% | — | — | |
| Q3 2013 | -2.1% | — | — | |
| Q2 2013 | +4.1% | — | — | |
| Q1 2013 | +3.2% | — | — | |
| Q4 2012 | -4.3% | — | — | |
| Q3 2012 | -1.1% | — | — | |
| Q2 2012 | +0.0% | — | — | |
| Q4 2011 | -4.6% | — | — | |
| Q1 2012 | +1.2% | — | — | |
| Q3 2011 | -2.6% | — | — | |
| Q2 2011 | -1.0% | — | — | |
| Q1 2011 | -0.5% | — | — | |
| Q4 2010 | +2.0% | — | — | |
| Q3 2010 | +1.6% | — | — | |
| Q2 2010 | -2.6% | — | — | |
| Q1 2009 | +0.5% | — | — | |
| Q1 2010 | -1.4% | — | — | |
| Q4 2007 | -1.2% | — | — | |
| Q2 2009 | -1.2% | — | — | |
| Q4 2009 | -1.2% | — | — | |
| Q3 2009 | +2.5% | — | — | |
| Q3 2008 | +2.5% | — | — | |
| Q4 2008 | +2.5% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro